Preparation and in vitro delivery performance of chitosan–alginate microcapsule for IgG

Figures & data

Figure 1. The effect of chitosan concentration on the microcapsule property. (a) LC and EE, (b) accumulative release. Other components include 1% (w/v) CaCl₂, 2% (w/v) sodium alginate and 25% (w/w) BSA.

Figure 2. The effect of CaCl₂ level on the microcapsules’ property. (a) LC and EE, (b) accumulative release. Other components include 0.1% (w/v) chitosan, 2% (w/v) sodium alginate and 25% (w/w) BSA.

Figure 3. The effect of sodium alginate concentration on the microcapsules’ property. (a) LC and EE, (b) accumulative release. Other components include 0.1% (w/v) chitosan, 0.5% (w/v) CaCl₂ and 25% (w/w) BSA.

Figure 4. The effect of BSA loading rate (BSA/sodium alginate, w/w) on the microcapsules’ property. (a) LC and EE, (b) accumulative release. Other components include 0.1% (w/v) chitosan, 0.5% (w/v) CaCl₂ and 2% (w/v) sodium alginate.

Figure 5. The release profile of IgG microcapsules in simulated gastrointestinal fluid in vitro. Microcapsules were directly exposed to SIF in control.